S&P 500

6.061,48

0,39%

Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.

Registrieren

VCNX Vaccinex Inc

1,41

0,00 (0,00%)

05 Feb 2025 - Geschlossen

Verzögert um 15 Minuten

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

null

Vaccinex (NASDAQ:VCNX)
Historical Stock Chart
Von Jan 2025 bis Feb 2025

Vaccinex (NASDAQ:VCNX)
Historical Stock Chart
Von Feb 2024 bis Feb 2025

News Vaccinex Inc

Form 8-K - Current report
Dienstag 17 Dezember 2024 (2 Monate vor) • Edgar (US Regulatory)

Vaccinex Announces Receipt of Delisting Notification from Nasdaq
Dienstag 17 Dezember 2024 (2 Monate vor) • GlobeNewswire Inc.

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
Montag 18 November 2024 (3 Monate vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Montag 18 November 2024 (3 Monate vor) • Edgar (US Regulatory)

Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Montag 18 November 2024 (3 Monate vor) • GlobeNewswire Inc.

Form 8-K - Current report
Donnerstag 14 November 2024 (3 Monate vor) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Donnerstag 14 November 2024 (3 Monate vor) • Edgar (US Regulatory)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Donnerstag 14 November 2024 (3 Monate vor) • Edgar (US Regulatory)

Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC
Donnerstag 7 November 2024 (3 Monate vor) • GlobeNewswire Inc.

Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
Dienstag 5 November 2024 (3 Monate vor) • GlobeNewswire Inc.

Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain
Donnerstag 31 Oktober 2024 (3 Monate vor) • GlobeNewswire Inc.

Weitere Vaccinex Inc News-Artikel

TSX

FTT

Finning

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

VCNX Vaccinex Inc

News Vaccinex Inc

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

VCNX Vaccinex Inc

News Vaccinex Inc

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen